title: Platelet and red blood cell utilization and transfusion independence in umbilical cord blood and allogeneic peripheral blood hematopoietic cell transplants.
abstract: Allogeneic hematopoietic cell transplantation (HCT) recipients have substantial transfusion requirements. Factors associated with increased transfusions and the extent of blood product use in umbilical cord blood (UCB) recipients are uncertain. We reviewed blood product use in 229 consecutive adult recipients of allogeneic HCT at the University of Minnesota: 147 with leukemia, 82 lymphoma or myeloma; 58% received unrelated UCB and 43% sibling donor peripheral blood stem cell (PBSC) grafts. Although neutrophil recovery was prompt (UCB median 17, range: 2-45 days, and PBSC 14, range: 3-34 days), only 135 of 229 (59% cumulative incidence) achieved red blood cell (RBC) independence and 157 (69%) achieved platelet independence by 6 months. Time to platelet independence was prolonged in UCB recipients (median UCB 41 versus PBSC 14 days) and in patients who had received a prior transplant (median 48 versus 32 days). Patients who received UCB grafts required more RBC through day 60 post-HCT (mean UCB 7.8 (95% confidence interval [CI] 6.7-8.9) versus PBSC 5.2 (3.7-6.7) transfusions, P = .04), and more platelet transfusions (mean 25.2 (95% CI 22.1-28.2) versus 12.9 (9.4-16.4), P < .01) compared to PBSC recipients. Patients receiving myeloablative (MA) conditioning required more RBC and platelet transfusions during the first 2 months post-HCT compared to reduced-intensity conditioning (RIC) (7.4 versus 6.2, P = .30 for RBC; 23.2 versus 17.5, P = .07 for platelets). Despite prompt neutrophil engraftment, UCB recipients had delayed platelet recovery as well as more prolonged and costly blood product requirements. Enhanced approaches to accelerate multilineage engraftment could limit the transfusion-associated morbidity and costs accompanying UCB allotransplantation.
authors.affiliation: Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, Minnesota 55455, USA.
authors.forename: Melhem
authors.initials: M
authors.lastname: Solh
authors.forename: Claudio
authors.initials: C
authors.lastname: Brunstein
authors.forename: Shanna
authors.initials: S
authors.lastname: Morgan
authors.forename: Daniel
authors.initials: D
authors.lastname: Weisdorf
mesh_terms: D000328:Adult; D001792:Blood Platelets / Q000166:cytology; D001803:Blood Transfusion / Q000191:economics / Q000706:statistics & numerical data*; D002452:Cell Count; D036101:Cord Blood Stem Cell Transplantation; D004912:Erythrocytes / Q000166:cytology; D005199:Fanconi Anemia / Q000503:physiopathology / Q000628:therapy; D005260:Female; D005333:Fetus; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007938:Leukemia / Q000503:physiopathology / Q000628:therapy; D008223:Lymphoma / Q000503:physiopathology / Q000628:therapy; D008297:Male; D008910:Minnesota; D009101:Multiple Myeloma / Q000503:physiopathology / Q000628:therapy; D009504:Neutrophils / Q000166:cytology; D036102:Peripheral Blood Stem Cell Transplantation; D010976:Platelet Count; D017713:Platelet Transfusion / Q000191:economics / Q000706:statistics & numerical data*; D011247:Pregnancy; D014019:Tissue Donors; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous
references.citation: N Engl J Med. 2010 Feb 18;362(7):600-13
references.pmid: 20164484
references.citation: Am J Med Sci. 1986 Mar;291(3):147-51
references.pmid: 3456706
references.citation: Semin Hematol. 2009 Jul;46(3):289-312
references.pmid: 19549581
references.citation: Bone Marrow Transplant. 1996 Jun;17(6):1035-41
references.pmid: 8807111
references.citation: Bone Marrow Transplant. 1996 Nov;18(5):931-5
references.pmid: 8932847
references.citation: Transfusion. 2007 Sep;47(9):1700-9
references.pmid: 17725737
references.citation: Bone Marrow Transplant. 2009 Jun;43(12):935-40
references.pmid: 19139736
references.citation: Transfusion. 2005 Jul;45(7):1064-72
references.pmid: 15987349
references.citation: Recent Results Cancer Res. 1988;108:44-52
references.pmid: 3051211
references.citation: Curr Opin Hematol. 2001 Sep;8(5):319-25
references.pmid: 11604568
references.citation: Blood. 1998 May 15;91(10):3601-6
references.pmid: 9572994
references.citation: Transfusion. 2007 May;47(5):801-12
references.pmid: 17465944
references.citation: N Engl J Med. 1997 Dec 25;337(26):1870-5
references.pmid: 9407153
references.citation: Biol Blood Marrow Transplant. 2009 May;15(5):564-73
references.pmid: 19361748
references.citation: N Engl J Med. 1998 Nov 26;339(22):1565-77
references.pmid: 9828244
references.citation: Bone Marrow Transplant. 2002 Jul;30(2):63-8
references.pmid: 12132043
references.citation: Blood. 2003 Feb 15;101(4):1620-9
references.pmid: 12393457
references.citation: Ann Hematol. 1992 Aug;65(2):66-70
references.pmid: 1511059
references.citation: N Engl J Med. 1962 May 3;266:905-9
references.pmid: 13897369
references.citation: Blood. 2008 Oct 15;112(8):3036-47
references.pmid: 18583566
references.citation: J Clin Oncol. 2006 Sep 1;24(25):4150-7
references.pmid: 16896000
references.citation: Transfusion. 2004 Apr;44(4):501-8
references.pmid: 15043564
references.citation: Biol Blood Marrow Transplant. 2002;8(10):569-76
references.pmid: 12434952
references.citation: Exp Hematol. 2010 Jan;38(1):55-60
references.pmid: 19837124
references.citation: Blood. 2001 Dec 15;98(13):3584-8
references.pmid: 11739160
references.citation: Blood. 2009 Aug 20;114(8):1689-95
references.pmid: 19535797
references.citation: Blood. 1996 Aug 1;88(3):795-802
references.pmid: 8704232